Citeline Pharma R&D Review 2024: Pleasant Weather Ahead

Welcome to the 2024 edition of Pharmaprojects’ review of pharmaceutical R&D trends. For over three decades, I’ve annually examined the progress of pharma R&D, and in this report, we'll assess the current state of the industry. We'll look at trends across companies, therapeutic areas, diseases, targets, and drug types, using data primarily from Pharmaprojects, part of the Citeline suite, which has been tracking drug development globally since 1980.

This report will precede our yearly supplement that reviews the New Active Substance (NAS) launches from the previous year. We aim to gauge the pharma R&D climate, identifying where pressures are increasing or decreasing, and forecasting areas of growth or challenge.

Regular readers familiar with the report’s annual themes—ranging from astronomy to literature—will notice this year’s theme revolves around weather and climate change. This reflects not only the omnipresent impact of weather on our activities since the dawn of humanity but also underscores the pressing issue of climate change today.

Through this exploration, we hope to provide you with comprehensive insights, helping you understand which sectors of the industry might enjoy continued growth and which may face challenges.